Clearside Biomedical (CLSD) Scheduled to Post Quarterly Earnings on Tuesday

Clearside Biomedical (NASDAQ:CLSD) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.25 million. During the same quarter in the prior year, the firm earned ($0.15) earnings per share. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clearside Biomedical Trading Up 2.7 %

Clearside Biomedical stock opened at $1.14 on Friday. Clearside Biomedical has a 52 week low of $0.76 and a 52 week high of $2.12. The stock has a market cap of $85.19 million, a P/E ratio of -2.28 and a beta of 2.33. The stock has a 50 day moving average of $1.18 and a 200-day moving average of $1.19.

Insider Buying and Selling at Clearside Biomedical

In related news, insider Ngai Hang Victor Chong purchased 36,500 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $36,500.00. Following the transaction, the insider now owns 100,000 shares of the company’s stock, valued at $100,000. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 9.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Chardan Capital reissued a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a report on Monday, October 14th. StockNews.com downgraded Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday. Needham & Company LLC lifted their target price on Clearside Biomedical from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Clearside Biomedical in a report on Tuesday, August 27th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.17.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.